Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Raymond James to Market Perform

Flexion Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Flexion Therapeutics Downgraded by Raymond James on 10-12-21. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of Strong-Buy.

View More Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Raymond James to Market Perform

Flexion Therapeutics (NASDAQ:FLXN) Downgraded by BMO Capital Markets – 2 stars to Market Perform

Flexion Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Flexion Therapeutics Downgraded by BMO Capital Markets – 2 stars on 10-12-21. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of Outperform.

View More Flexion Therapeutics (NASDAQ:FLXN) Downgraded by BMO Capital Markets – 2 stars to Market Perform

Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Needham & Company LLC to Hold

Flexion Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Flexion Therapeutics Downgraded by Needham & Company LLC on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Needham & Company LLC to Hold

Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Zacks Investment Research to Hold

Flexion Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Flexion Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Zacks Investment Research to Hold

Flexion Therapeutics (FLXN) Downgraded by Credit Suisse Group AG to Neutral

Flexion Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Flexion Therapeutics Downgraded by Credit Suisse Group AG on 10/11/2021. In a note to investors, the firm issued a new rating of Neutral. The analysts previously had rating of Outperform.

View More Flexion Therapeutics (FLXN) Downgraded by Credit Suisse Group AG to Neutral